A Phase 4 interventional study of Adalimumab and Placebo in Rheumatoid Arthritis and Musculoskeletal and Connective Tissue Diseases, sponsored by AbbVie. Completed at 70 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-25.
Sponsored by AbbVie · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 47th largest by enrollment, is one of 8 that started in 2015, is one of 33 in phase 4, and was the 63rd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 149 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
80 studies in Arthritis, Rheumatoid by AbbVie: 5 open now, 6 under way, 1 of them phase 3. Of 71 finished, 54 (76%) have results posted.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 23rd largest by enrollment of the 38 interventional ones that give a count, is one of 9 that started in 2015, is one of 4 in phase 4, and was the 42nd registered.
AbbVie’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 80 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to investigate the association between residual disease activity at Baseline as detected by Magnetic Resonance Imaging (MRI) and the occurrence of flares in participants with rheumatoid arthritis (RA) randomized to an adalimumab dose tapering regimen controlled by adalimumab withdrawal.
This was a Phase 4, multicenter, randomized, double-blind, parallel-group study. The study included a Screening period of up to 28 days (unless extended with justification approved by study-designated physician), a 4-week Lead-In Period with open label (OL) 40 mg adalimumab administered subcutaneously (sc) every other week (eow), and a randomized 36-week double-blind period with 40 mg adalimumab sc every 3 weeks (q3wks; tapering arm) or placebo sc q3wks (withdrawal arm). Participants were randomized in a 5:1 ratio (tapering arm: withdrawal arm) after confirmation of meeting the disease activity score (DAS) criteria. Participants who experienced a protocol-defined flare at any time were to enter a rescue arm with OL 40 mg adalimumab administered sc eow for 16 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant must have met the following criteria:
Participant must be in sustained clinical remission based on the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
40 mg adalimumab administered subcutaneously every other week (eow) from Week 0 to Week 4 (Lead-in Period)
Biological: Adalimumab
40 mg adalimumab administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
Biological: Adalimumab
Placebo administered subcutaneously every three weeks from Week 4 to Week 40 (Double-blind Period)
Other: Placebo
40 mg adalimumab administered subcutaneously every other week from Flare Week 0 to Flare Week 16 (Open-label Rescue Period)
Biological: Adalimumab
Pre-filled syringe, administered by subcutaneous injection
Also known as: ABT-D2E7, Humira
Pre-filled syringe, administered by subcutaneous injection in the Double-blind period
Association Between Baseline Hand and Wrist Synovitis Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Score and Flare up to Week 40 in the Tapering Arm
Synovitis was assessed in three wrist regions (the distal radioulnar joint; the radiocarpal joint; the intercarpal and carpometacarpal joints) and in each Metacarpophalangeal joint (MCP) joint. The first carpometacarpal joint and the first MCP joint are not scored. The scale is 0-3. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment. Flare is defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\]. The association between baseline hand and wrist synovitis RAMRIS score and occurrence of rheumatoid arthritis flare up to Week 40 in the Tapering arm was examined using logistic regression, and the 95% confidence interval of the odds ratio was calculated.
Time frame: From Week 4 to Week 40
Association Between Baseline Bone Marrow Edema RAMRIS Score and Flare up to Week 40 in the Tapering Arm
Bone marrow edema in each bone was scored separately. The scale is 0-3 based on the proportion of bone with edema, as follows-0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%. Flare is defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\]. The association between baseline bone marrow edema rheumatoid arthritis MRI scoring system (RAMRIS) score and occurrence of rheumatoid arthritis flare up to Week 40 in the Tapering arm was examined using logistic regression, and the 95% confidence interval of the odds ratio was calculated.
Time frame: From Week 4 to Week 40
Association Between a Composite of Baseline Hand and Wrist Synovitis and Bone Marrow Edema RAMRIS Scores and Flare up to Week 40 in the Tapering Arm
The composite score is the sum of the baseline hand and wrist synovitis and bone marrow edema RAMRIS scores. Flare is defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\]. The association between the composite baseline hand and wrist synovitis score and baseline bone marrow edema rheumatoid arthritis MRI scoring system (RAMRIS) score and occurrence of rheumatoid arthritis flare up to Week 40 in the Tapering arm was examined using logistic regression, and the 95% confidence interval of the odds ratio was calculated.
Time frame: From Week 4 to Week 40
Median Time to Flare
Time to flare was defined as the number of weeks from the date of the first dose of study drug in the Double-blind period to the date of flare.
Time frame: From Week 4 to Week 40
Physicians' Assessment of Flare Severity
Physicians rated the severity of flare at the Flare Week 0 visit from 0 (not severe) to 10 (very severe). The number of participants within each level of flare severity is presented.
Time frame: At the Flare Week 0 Visit
Participants' Assessment of Flare Severity
Participants rated the severity of flare at the Flare Week 0 visit from 0 (not severe) to 10 (very severe). The number of participants within each level of flare severity is presented.
Time frame: At the Flare Week 0 Visit
Percentage of Participants With a Flare
Flare was defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\].
Time frame: From Week 4 to Week 40
Number of Participants Who Regained Clinical Remission in the Open-Label Rescue Arm Over Time
The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 (ESR) score. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Clinical remission was defined as DAS28 (ESR) \< 2.6.
Time frame: From Flare Week 0 to Flare Week 16
Median Time to Clinical Remission From the Occurrence of Flare
The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 (ESR) score. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Clinical remission was defined as DAS28 (ESR) \< 2.6. Time to clinical remission was defined as the number of weeks from the occurrence of flare to the first date of clinical remission.
Time frame: From Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Disease Activity Score 28 (DAS28)
The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 (ESR) score. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Negative values indicate improvement from baseline.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Clinical Disease Activity Index (CDAI) Score
The CDAI is a validated measure of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global health assessed by the participant on a visual analogue scale from 0 to 10 (cm), and global health assessed by an investigator on a visual analogue scale from 0 to 10 (cm) were included in the CDAI score. Scores on the CDAI range from 0 to 76; higher scores indicate more disease activity. Negative values indicate improvement from the Double-blind baseline score.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Simplified Disease Activity Index (SDAI) Score
The SDAI is a validated measure of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global health assessed by the participant on a visual analogue scale from 0 to 10 (cm), global health assessed by an investigator on a visual analogue scale from 0 to 10 (cm), and serum levels of C-reactive protein levels (mg/dL) were included in the SDAI score. Scores on the SDAI range from 0 to 86; higher scores indicate more disease activity. Negative values indicate improvement from the Double-blind baseline score.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Number of Participants Maintaining Clinical Remission Defined By DAS28 (ESR) < 2.6, SDAI ≤ 3.3, and CDAI ≤ 2.8 at Each Visit By Treatment Arm
The maintenance of clinical remission after regaining remission during the Open-label rescue period was defined as either Disease Activity Score 28 (DAS28 ESR) \< 2.6, Simplified Disease Activity Index (SDAI) score ≤ 3.3, or Clinical Disease Activity Index (CDAI) score ≤ 2.8).
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline to Week 40 or Final Visit in Magnetic Resonance Imaging (MRI) Synovitis Score
Synovitis was assessed in three wrist regions (the distal radioulnar joint; the radiocarpal joint; the intercarpal and carpometacarpal joints) and in each Metacarpophalangeal joint (MCP) joint. The first carpometacarpal joint and the first MCP joint are not scored. The scale is 0-3. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment.
Time frame: From Week 4 to Week 40 or Final visit
Mean Change From Double-blind Baseline to Week 40 or Final Visit in Bone Marrow Edema (BME) Score
Bone edema in each bone was scored separately. The scale is 0-3 based on the proportion of bone with edema, as follows-0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%.
Time frame: From Week 4 to Week 40 or Final visit
Mean Change From Double-blind Baseline to Week 40 or Final Visit in Bone Erosions Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Score
Bone erosions in each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) were scored separately. The scale is 0-10, based on the proportion of eroded bone compared to the ''assessed bone volume'', judged on all available images-0: no erosion; 1: 1-10% of bone eroded; 2; 11-20%, etc.
Time frame: From Week 4 to Week 40 or Final Visit
Mean Change From Double-blind Baseline in Health Assessment Questionnaire- Disability Index (HAQ-DI) Score Over Time
The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is ≥ 0.22.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Number of Participants With Health Assessment Questionnaire- Disability Index (HAQ-DI) Score ≤ 0.5 at Double-blind Baseline and at Week 40
The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The number of participants with HAQ-DI score ≤ 0.5 (considered to be normal) was recorded.
Time frame: Week 4 and Week 40
Mean Change From Double-blind Baseline in Routine Assessment of Patient Index Data (RAPID3) Questionnaire Scores Assessed During In-office Visits
The RAPID3 is an activity index derived from the Multi-dimensional Health Assessment Questionnaire (MD-HAQ). It includes an assessment of physical function, a pain Visual Analog Scale (VAS), and a participant global assessment of disease activity VAS. The total RAPID3 score ranges from 0 to 30 where higher scores represent severe disease. Negative values indicate improvement from the Double-blind baseline score.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Flare Week 0 in Routine Assessment of Patient Index Data (RAPID3) Questionnaire Scores Assessed at Home
The RAPID3 is an activity index derived from the Multi-dimensional Health Assessment Questionnaire (MD-HAQ). It includes an assessment of physical function, a pain Visual Analog Scale (VAS), and a participant global assessment of disease activity VAS. The total RAPID3 score ranges from 0 to 30 where higher scores represent severe disease. Negative values indicate improvement from the Double-blind baseline score.
Time frame: Flare Week 0 and Flare Weeks 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15
Mean Change From Double-blind Baseline in Swollen Joint Count 28
Twenty-eight joints, excluding hip joints, were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 28 (worst possible score/28 joints with swelling). Negative values indicate improvement from baseline.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Swollen Joint Count 66
Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Tender Joint Count 28
Twenty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 28 (worst possible score/28 joints with tenderness). Negative values indicate improvement from baseline.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Tender Joint Count 68
Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Participant's Global Assessment of Disease Activity
Participants rated the severity of their rheumatoid arthritis symptoms and how well they were doing during the last 24 hours by placing a vertical mark on a line with a range of 0 (very well) to 100 mm (very poorly). Negative values indicate improvement from baseline.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Participant's Global Assessment of Rheumatoid Arthritis Pain
Participants rated the severity of their rheumatoid arthritis pain in the past week by placing a vertical mark on a line with a range of 0 (no pain) to 100 mm (severe pain). Negative values indicate improvement from baseline.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Physician's Global Assessment of Disease Activity
Physicians assessed participants' current rheumatoid arthritis disease activity at the time of the visit (independent of the participant's self-assessment) by placing a vertical mark on a line with a range of 0 (very low) to 100 mm (very high). Negative values indicate improvement from baseline.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Morning Stiffness Duration
The duration of morning stiffness was reported by participants as the average daily length during the past week in minutes (from time of awaking to time of maximal improvement). Negative values indicate improvement from baseline.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Morning Stiffness Severity
Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe". Negative values indicate improvement from baseline.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Participant's Assessment of Sleep Disturbance
Participants rated the severity of their sleep disturbance in the past week by placing a vertical mark on a line with a range of 0 (sleep is no problem) to 100 mm (sleep is a major problem). Negative values indicate improvement from baseline.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Effectiveness Score
Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.
Time frame: At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Side Effects Score
Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.
Time frame: At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Convenience Score
Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.
Time frame: At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction Score
Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.
Time frame: At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Work Productivity and Activity Impairment (WPAI) Overall Work Impairment and Activity Impairment Scores
The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in rheumatoid arthritis consisting of 6 questions, based on participant recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.
Time frame: At Weeks 4, 28, and 40 and Flare Weeks 0, 10, and 16
Mean Change From Double-blind Baseline in Short-Form 36 Version 2 Health Survey (SF-36v2) Physical Component Summary (PCS) Score
The SF-36v2 is a non-disease specific Health Related Quality of Life (HRQoL) instrument. The SF-36v2 comprises 36 total items (questions) targeting a subject's functional health and well-being in 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health) with a recall period of four weeks. Domain scores are aggregated into a Physical Component Summary (PCS) score and a Mental Component Summary (MCS) score. SF-36v2 scores for each domain and PCS/MCS range from 0-100: higher scores indicate a better state of health and a decrease from baseline represents worsening.
Time frame: At Weeks 4, 28, and 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Short-Form 36 Version 2 Health Survey (SF-36v2) Mental Component Summary (MCS) Score
The SF-36v2 is a non-disease specific Health Related Quality of Life (HRQoL) instrument. The SF-36v2 comprises 36 total items (questions) targeting a subject's functional health and well-being in 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health) with a recall period of four weeks. Domain scores are aggregated into a Physical Component Summary (PCS) score and a Mental Component Summary (MCS) score. SF-36v2 scores for each domain and PCS/MCS range from 0-100: higher scores indicate a better state of health and a decrease from baseline represents worsening.
Time frame: At Weeks 4, 28, and 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale
The FACIT-Fatigue questionnaire is a participant questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions on a scale from 'not at all' (0) to 'very much' (4). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A negative change from baseline indicates worsening.
Time frame: At Weeks 4, 16, 28, and 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Serum Levels of C-reactive Protein (CRP)
C-Reactive Protein (CRP; mg/L) was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Negative values indicate improvement from baseline.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
Mean Change From Double-blind Baseline in Serum Levels of Erythrocyte Sedimentation Rate (ESR)
Erythrocyte sedimentation rate (ESR; mm/hour) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. Negative values indicate improvement from baseline.
Time frame: From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16
| Milestone | Adalimumab 40 mg Eow | Adalimumab Tapering | Adalimumab Withdrawal Arm | Adalimumab Tapering to Rescue Arm | Adalimumab Withdrawal to Rescue Arm |
|---|---|---|---|---|---|
| Started | 149 | 0 | 0 | 0 | 0 |
| Participants treated in lead-in period | 146 | 0 | 0 | 0 | 0 |
| Completed | 112 | 0 | 0 | 0 | 0 |
| Not completed | 37 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 13 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 22 | 0 | 0 | 0 | 0 |
| Milestone | Adalimumab 40 mg Eow | Adalimumab Tapering | Adalimumab Withdrawal Arm | Adalimumab Tapering to Rescue Arm | Adalimumab Withdrawal to Rescue Arm |
|---|---|---|---|---|---|
| Started | 0 | 102 | 20 | 0 | 0 |
| Completed | 0 | 93 | 19 | 0 | 0 |
| Not completed | 0 | 9 | 1 | 0 | 0 |
| Withdrew: Withdrew consent | 0 | 4 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other, not specified | 0 | 4 | 1 | 0 | 0 |
| Milestone | Adalimumab 40 mg Eow | Adalimumab Tapering | Adalimumab Withdrawal Arm | Adalimumab Tapering to Rescue Arm | Adalimumab Withdrawal to Rescue Arm |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 31 | 8 |
| Correctly entered open-label rescue | 0 | 0 | 0 | 30 | 8 |
| Completed | 0 | 0 | 0 | 28 | 8 |
| Not completed | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Incorrectly entered open-label rescue | 0 | 0 | 0 | 1 | 0 |
Synovitis was assessed in three wrist regions (the distal radioulnar joint; the radiocarpal joint; the intercarpal and carpometacarpal joints) and in each Metacarpophalangeal joint (MCP) joint. The first carpometacarpal joint and the first MCP joint are not scored. The scale is 0-3. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment. Flare is defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\]. The association between baseline hand and wrist synovitis RAMRIS score and occurrence of rheumatoid arthritis flare up to Week 40 in the Tapering arm was examined using logistic regression, and the 95% confidence interval of the odds ratio was calculated.
| odds ratio | Adalimumab Tapering |
|---|---|
| Association Between Baseline Hand and Wrist Synovitis Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Score and Flare up to Week 40 in the Tapering Arm | 0.993 (0.822 to 1.199) |
Bone marrow edema in each bone was scored separately. The scale is 0-3 based on the proportion of bone with edema, as follows-0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%. Flare is defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\]. The association between baseline bone marrow edema rheumatoid arthritis MRI scoring system (RAMRIS) score and occurrence of rheumatoid arthritis flare up to Week 40 in the Tapering arm was examined using logistic regression, and the 95% confidence interval of the odds ratio was calculated.
| odds ratio | Adalimumab Tapering |
|---|---|
| Association Between Baseline Bone Marrow Edema RAMRIS Score and Flare up to Week 40 in the Tapering Arm | 0.959 (0.821 to 1.119) |
The composite score is the sum of the baseline hand and wrist synovitis and bone marrow edema RAMRIS scores. Flare is defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\]. The association between the composite baseline hand and wrist synovitis score and baseline bone marrow edema rheumatoid arthritis MRI scoring system (RAMRIS) score and occurrence of rheumatoid arthritis flare up to Week 40 in the Tapering arm was examined using logistic regression, and the 95% confidence interval of the odds ratio was calculated.
| odds ratio | Adalimumab Tapering |
|---|---|
| Association Between a Composite of Baseline Hand and Wrist Synovitis and Bone Marrow Edema RAMRIS Scores and Flare up to Week 40 in the Tapering Arm | 0.979 (0.885 to 1.084) |
Time to flare was defined as the number of weeks from the date of the first dose of study drug in the Double-blind period to the date of flare.
| weeks | Adalimumab Tapering | Adalimumab Withdrawal Arm |
|---|---|---|
| Median Time to Flare | NA (36.4 to NA) | NA (12.1 to NA) |
Physicians rated the severity of flare at the Flare Week 0 visit from 0 (not severe) to 10 (very severe). The number of participants within each level of flare severity is presented.
| Participants | Adalimumab Tapering | Adalimumab Withdrawal Arm |
|---|---|---|
| 0 | 1 | 1 |
| 1 | 2 | 0 |
| 2 | 3 | 0 |
| 3 | 3 | 1 |
| 4 | 6 | 2 |
| 5 | 1 | 1 |
| 6 | 4 | 0 |
| 7 | 1 | 0 |
| 8 | 0 | 0 |
| 9 | 0 | 0 |
| 10 | 0 | 0 |
| Missing | 9 | 3 |
Participants rated the severity of flare at the Flare Week 0 visit from 0 (not severe) to 10 (very severe). The number of participants within each level of flare severity is presented.
| Participants | Adalimumab Tapering | Adalimumab Withdrawal Arm |
|---|---|---|
| 0 | 1 | 0 |
| 1 | 2 | 1 |
| 2 | 2 | 2 |
| 3 | 3 | 0 |
| 4 | 4 | 0 |
| 5 | 1 | 1 |
| 6 | 4 | 1 |
| 7 | 1 | 0 |
| 8 | 2 | 0 |
| 9 | 0 | 0 |
| 10 | 2 | 0 |
| Missing | 8 | 3 |
Flare was defined as an increase from Double-blind Baseline in DAS (Disease Activity Score) 28 erythrocyte sedimentation rate (ESR) of \> 0.6 AND DAS28 \[ESR\] \> 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 \[ESR\].
| percentage of participants | Adalimumab Tapering | Adalimumab Withdrawal Arm |
|---|---|---|
| Percentage of Participants With a Flare | 36.3 (27.0 to 46.4) | 45.0 (23.1 to 68.5) |
The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 (ESR) score. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Clinical remission was defined as DAS28 (ESR) \< 2.6.
| Participants | Adalimumab Tapering | Adalimumab Withdrawal Arm |
|---|---|---|
| Flare Week 0 | 3 | 1 |
| Flare Week 4 | 14 | 1 |
| Flare Week 10 | 17 | 3 |
| Flare Week 16 | 13 | 4 |
The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 (ESR) score. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Clinical remission was defined as DAS28 (ESR) \< 2.6. Time to clinical remission was defined as the number of weeks from the occurrence of flare to the first date of clinical remission.
| weeks | Adalimumab Tapering | Adalimumab Withdrawal Arm |
|---|---|---|
| Median Time to Clinical Remission From the Occurrence of Flare | 6.1 (4.1 to 16.3) | 18.0 (0.1 to 18.0) |
The Disease Activity Score 28 (DAS28) is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, the erythrocyte sedimentation rate (ESR; mm/hour), and the participant's assessment of global disease activity (on a visual analog scale \[VAS\] from 0 to 10 cm) are included in the DAS28 (ESR) score. Scores on the DAS28 range from 0 to 10; higher scores indicate more disease activity. Negative values indicate improvement from baseline.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 0.7 ± 1.27 | 0.1 ± 0.46 |
| Double Blind Week 10- Withdrawal Arm | 0.1 ± 0.47 | 0.1 ± 0.55 |
| Double Blind Week 16- Tapering Arm | 1.2 ± 1.34 | 0.1 ± 0.39 |
| Double Blind Week 16- Withdrawal Arm | 0.9 ± 0.58 | 0.0 ± 0.43 |
| Double Blind Week 22- Tapering Arm | 0.7 ± 1.18 | -0.0 ± 0.53 |
| Double Blind Week 22- Withdrawal Arm | 0.5 ± 0.31 | 0.1 ± 0.24 |
| Double Blind Week 28- Tapering arm | 0.8 ± 1.16 | 0.1 ± 0.50 |
| Double Blind Week 28- Withdrawal arm | 1.0 ± 1.54 | 0.2 ± 0.25 |
| Double Blind Week 34- Tapering Arm | 0.7 ± 0.59 | -0.0 ± 0.54 |
| Double Blind Week 34- Withdrawal Arm | -0.7 ± 0.11 | -0.0 ± 0.46 |
| Double Blind Week 40- Tapering Arm | 1.5 ± 1.20 | 0.0 ± 0.52 |
| Double Blind Week 40- Withdrawal Arm | 0.8 ± 2.18 | 0.2 ± 0.38 |
| Flare Week 0- Tapering Arm | 2.3 ± 1.15 | — |
| Flare Week 0- Withdrawal Arm | 1.9 ± 0.96 | — |
| Flare Week 4- Tapering Arm | 1.3 ± 1.05 | — |
| Flare Week 4- Withdrawal Arm | 1.2 ± 1.14 | — |
| Flare Week 10- Tapering Arm | 0.9 ± 0.81 | — |
| Flare Week 10- Withdrawal Arm | 0.7 ± 0.50 | — |
| Flare Week 16- Tapering Arm | 1.2 ± 1.04 | — |
| Flare Week 16- Withdrawal Arm | 0.6 ± 0.80 | — |
The CDAI is a validated measure of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global health assessed by the participant on a visual analogue scale from 0 to 10 (cm), and global health assessed by an investigator on a visual analogue scale from 0 to 10 (cm) were included in the CDAI score. Scores on the CDAI range from 0 to 76; higher scores indicate more disease activity. Negative values indicate improvement from the Double-blind baseline score.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 4.4 ± 7.68 | 0.6 ± 1.34 |
| Double Blind Week 10- Withdrawal Arm | 1.0 ± 2.45 | 1.4 ± 2.85 |
| Double Blind Week 16- Tapering Arm | 7.0 ± 9.35 | 0.4 ± 1.30 |
| Double Blind Week 16- Withdrawal Arm | 2.9 ± 2.42 | -0.1 ± 0.88 |
| Double Blind Week 22- Tapering Arm | 3.2 ± 4.98 | 0.3 ± 1.38 |
| Double Blind Week 22- Withdrawal Arm | 2.2 ± 1.93 | 0.1 ± 0.73 |
| Double Blind Week 28- Tapering arm | 3.7 ± 6.19 | 0.5 ± 1.37 |
| Double Blind Week 28- Withdrawal arm | 6.3 ± 8.40 | -0.1 ± 0.80 |
| Double Blind Week 34- Tapering Arm | 2.7 ± 3.04 | 0.2 ± 1.08 |
| Double Blind Week 34- Withdrawal Arm | -0.1 ± 0.14 | 0.0 ± 0.92 |
| Double Blind Week 40- Tapering Arm | 7.4 ± 10.04 | 0.1 ± 1.33 |
| Double Blind Week 40- Withdrawal Arm | 7.7 ± 11.38 | -0.3 ± 0.48 |
| Flare Week 0- Tapering Arm | 12.3 ± 9.56 | — |
| Flare Week 0- Withdrawal Arm | 9.4 ± 9.13 | — |
| Flare Week 4- Tapering Arm | 5.0 ± 6.55 | — |
| Flare Week 4- Withdrawal Arm | 5.4 ± 9.59 | — |
| Flare Week 10- Tapering Arm | 3.5 ± 4.55 | — |
| Flare Week 10- Withdrawal Arm | 3.6 ± 2.52 | — |
| Flare Week 16- Tapering Arm | 4.5 ± 6.14 | — |
| Flare Week 16- Withdrawal Arm | 2.8 ± 4.19 | — |
The SDAI is a validated measure of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, global health assessed by the participant on a visual analogue scale from 0 to 10 (cm), global health assessed by an investigator on a visual analogue scale from 0 to 10 (cm), and serum levels of C-reactive protein levels (mg/dL) were included in the SDAI score. Scores on the SDAI range from 0 to 86; higher scores indicate more disease activity. Negative values indicate improvement from the Double-blind baseline score.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 3.7 ± 8.57 | 0.8 ± 1.85 |
| Double Blind Week 10- Withdrawal Arm | 0.9 ± 2.59 | 1.3 ± 2.67 |
| Double Blind Week 16- Tapering Arm | 6.3 ± 10.25 | 0.4 ± 1.35 |
| Double Blind Week 16- Withdrawal Arm | 3.6 ± 2.80 | -0.1 ± 0.90 |
| Double Blind Week 22- Tapering Arm | 3.6 ± 5.18 | 0.3 ± 1.47 |
| Double Blind Week 22- Withdrawal Arm | 2.3 ± 1.95 | -0.0 ± 0.88 |
| Double Blind Week 28- Tapering arm | 3.8 ± 6.34 | 0.4 ± 1.37 |
| Double Blind Week 28- Withdrawal arm | 6.4 ± 8.40 | 0.1 ± 1.61 |
| Double Blind Week 34- Tapering Arm | 3.0 ± 3.29 | 0.2 ± 1.17 |
| Double Blind Week 34- Withdrawal Arm | 0.1 ± 0.33 | 0.1 ± 1.07 |
| Double Blind Week 40- Tapering Arm | 7.5 ± 10.27 | 0.1 ± 1.37 |
| Double Blind Week 40- Withdrawal Arm | 8.5 ± 10.23 | -0.3 ± 0.62 |
| Flare Week 0- Tapering Arm | 11.6 ± 11.17 | — |
| Flare Week 0- Withdrawal Arm | 9.9 ± 8.31 | — |
| Flare Week 4- Tapering Arm | 4.1 ± 8.73 | — |
| Flare Week 4- Withdrawal Arm | 5.2 ± 9.64 | — |
| Flare Week 10- Tapering Arm | 2.5 ± 7.53 | — |
| Flare Week 10- Withdrawal Arm | 3.5 ± 2.51 | — |
| Flare Week 16- Tapering Arm | 3.6 ± 6.63 | — |
| Flare Week 16- Withdrawal Arm | 2.7 ± 4.20 | — |
The maintenance of clinical remission after regaining remission during the Open-label rescue period was defined as either Disease Activity Score 28 (DAS28 ESR) \< 2.6, Simplified Disease Activity Index (SDAI) score ≤ 3.3, or Clinical Disease Activity Index (CDAI) score ≤ 2.8).
| Participants | DAS28 (ESR) < 2.6 | SDAI ≤ 3.3 | CDAI ≤ 2.8 |
|---|---|---|---|
| Double Blind Baseline- Tapering Arm | 102 | 89 | 85 |
| Double Blind Baseline- Withdrawal Arm | 20 | 19 | 19 |
| Double Blind Week 10- Tapering Arm | 85 | 63 | 62 |
| Double Blind Week 10- Withdrawal Arm | 18 | 16 | 14 |
| Double Blind Week 16- Tapering Arm | 78 | 64 | 62 |
| Double Blind Week 16- Withdrawal arm | 15 | 13 | 15 |
| Double Blind Week 22- Tapering Arm | 75 | 59 | 58 |
| Double Blind Week 22- Withdrawal Arm | 14 | 13 | 13 |
| Double Blind Week 28- Tapering Arm | 69 | 58 | 57 |
| Double Blind Week 28- Withdrawal Arm | 13 | 12 | 13 |
| Double Blind Week 34- Tapering Arm | 70 | 58 | 58 |
| Double Blind Week 34- Withdrawal Arm | 13 | 13 | 13 |
| Double Blind Week 40- Tapering Arm | 64 | 57 | 56 |
| Double Blind Week 40- Withdrawal Arm | 11 | 12 | 12 |
| Flare Week 0- Tapering Arm | 4 | 4 | 4 |
| Flare Week 0- Withdrawal Arm | 1 | 0 | 2 |
| Flare Week 4- Tapering Arm | 14 | 13 | 13 |
| Flare Week 4- Withdrawal Arm | 1 | 2 | 2 |
| Flare Week 10- Tapering Arm | 17 | 14 | 14 |
| Flare Week 10- Withdrawal Arm | 3 | 2 | 2 |
| Flare Week 16- Tapering Arm | 13 | 13 | 13 |
| Flare Week 16- Withdrawal Arm | 4 | 4 | 4 |
Synovitis was assessed in three wrist regions (the distal radioulnar joint; the radiocarpal joint; the intercarpal and carpometacarpal joints) and in each Metacarpophalangeal joint (MCP) joint. The first carpometacarpal joint and the first MCP joint are not scored. The scale is 0-3. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 40- Tapering Arm | -0.1 ± 1.20 | 0.1 ± 1.33 |
| Double Blind Week 40- Withdrawal Arm | 0.0 | -0.1 ± 0.90 |
| Flare Week 16- Tapering Arm | 0.8 ± 1.84 | — |
| Flare Week 16- Withdrawal Arm | 0.1 ± 1.81 | — |
Bone edema in each bone was scored separately. The scale is 0-3 based on the proportion of bone with edema, as follows-0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 40- Tapering Arm | -0.5 ± 0.84 | 0.0 ± 1.07 |
| Double Blind Week 40- Withdrawal Arm | 0.0 | 1.2 ± 3.52 |
| Flare Week 16- Tapering Arm | -0.1 ± 0.47 | — |
| Flare Week 16- Withdrawal Arm | 0.3 ± 0.38 | — |
Bone erosions in each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) were scored separately. The scale is 0-10, based on the proportion of eroded bone compared to the ''assessed bone volume'', judged on all available images-0: no erosion; 1: 1-10% of bone eroded; 2; 11-20%, etc.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 40- Tapering Arm | -0.5 ± 1.73 | 0.1 ± 0.52 |
| Double Blind Week 40- Withdrawal Arm | -2.0 | 0.0 ± 1.08 |
| Flare Week 16- Tapering Arm | 0.3 ± 1.02 | — |
| Flare Week 16- Withdrawal Arm | 0.1 ± 0.88 | — |
The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The minimal clinically important difference (MCID) defined for the HAQ-DI is ≥ 0.22.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 0.1 ± 0.3 | 0.0 ± 0.18 |
| Double Blind Week 10- Withdrawal Arm | 0.3 ± 0.61 | 0.0 ± 0.17 |
| Double Blind Week 16- Tapering Arm | 0.2 ± 0.40 | -0.0 ± 0.28 |
| Double Blind Week 16- Withdrawal Arm | 0.3 ± 0.54 | -0.0 ± 0.12 |
| Double Blind Week 22- Tapering Arm | 0.1 ± 0.37 | -0.0 ± 0.26 |
| Double Blind Week 22- Withdrawal Arm | 0.4 ± 0.79 | 0.1 ± 0.39 |
| Double Blind Week 28- Tapering Arm | 0.2 ± 0.43 | -0.0 ± 0.27 |
| Double Blind Week 28- Withdrawal Arm | 0.7 ± 0.69 | -0.1 ± 0.15 |
| Double Blind Week 34- Tapering Arm | 0.3 ± 0.49 | -0.0 ± 0.30 |
| Double Blind Week 34- Withdrawal Arm | 0.2 ± 0.27 | 0.1 ± 0.17 |
| Double Blind Week 40- Tapering Arm | 0.4 ± 0.40 | -0.1 ± 0.33 |
| Double Blind Week 40- Withdrawal Arm | 1.9 | 0.0 ± 0.16 |
| Flare Week 0- Tapering Arm | 0.4 ± 0.57 | — |
| Flare Week 0- Withdrawal Arm | 0.3 ± 0.29 | — |
| Flare Week 4- Tapering Arm | 0.2 ± 0.49 | — |
| Flare Week 4- Withdrawal Arm | 0.2 ± 0.35 | — |
| Flare Week 10- Tapering Arm | 0.1 ± 0.24 | — |
| Flare Week 10- Withdrawal Arm | 0.1 ± 0.20 | — |
| Flare Week 16- Tapering Arm | 0.2 ± 0.39 | — |
| Flare Week 16- Withdrawal Arm | 0.1 ± 0.24 | — |
The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a participant-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability. The number of participants with HAQ-DI score ≤ 0.5 (considered to be normal) was recorded.
| Participants | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 4- Tapering Arm | 21 | 50 |
| Double Blind Week 4- Withdrawal Arm | 7 | 10 |
| Double Blind Week 40- Tapering Arm | 2 | 48 |
| Double Blind Week 40- Withdrawal Arm | 0 | 9 |
The RAPID3 is an activity index derived from the Multi-dimensional Health Assessment Questionnaire (MD-HAQ). It includes an assessment of physical function, a pain Visual Analog Scale (VAS), and a participant global assessment of disease activity VAS. The total RAPID3 score ranges from 0 to 30 where higher scores represent severe disease. Negative values indicate improvement from the Double-blind baseline score.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 1.9 ± 3.92 | 0.7 ± 3.20 |
| Double Blind Week 10- Withdrawal Arm | 1.4 ± 3.73 | 1.5 ± 4.67 |
| Double Blind Week 16- Tapering Arm | 4.7 ± 5.66 | 0.8 ± 2.80 |
| Double Blind Week 16- Withdrawal Arm | 2.5 ± 4.59 | 0.1 ± 1.37 |
| Double Blind Week 22- Tapering Arm | 2.6 ± 4.83 | 0.3 ± 2.83 |
| Double Blind Week 22- Withdrawal arm | 3.6 ± 4.18 | 0.6 ± 3.31 |
| Double Blind Week 28- Tapering arm | 2.2 ± 4.20 | 0.6 ± 2.47 |
| Double Blind Week 28- Withdrawal Arm | 3.7 ± 4.45 | -0.3 ± 1.61 |
| Double Blind Week 34- Tapering Arm | 2.2 ± 3.77 | -0.0 ± 1.93 |
| Double Blind Week 34- Withdrawal Arm | 1.9 ± 2.62 | 1.6 ± 2.33 |
| Double Blind Week 40- Tapering Arm | 4.7 ± 6.22 | 0.0 ± 2.39 |
| Double Blind Week 40- Withdrawal Arm | 0.4 ± 0.92 | 0.8 ± 1.62 |
| Flare Week 0- Tapering Arm | 6.1 ± 6.64 | — |
| Flare Week 0- Withdrawal Arm | 3.9 ± 5.60 | — |
| Flare Week 4- Tapering Arm | 3.1 ± 5.38 | — |
| Flare Week 4- Withdrawal Arm | 3.2 ± 4.15 | — |
| Flare Week 10- Tapering Arm | 2.8 ± 3.93 | — |
| Flare Week 10- Withdrawal Arm | 2.3 ± 2.61 | — |
| Flare Week 16- Tapering Arm | 2.9 ± 4.22 | — |
| Flare Week 16- Withdrawal Arm | 2.1 ± 3.01 | — |
The RAPID3 is an activity index derived from the Multi-dimensional Health Assessment Questionnaire (MD-HAQ). It includes an assessment of physical function, a pain Visual Analog Scale (VAS), and a participant global assessment of disease activity VAS. The total RAPID3 score ranges from 0 to 30 where higher scores represent severe disease. Negative values indicate improvement from the Double-blind baseline score.
| units on a scale | Flared Participants |
|---|---|
| Flare Week 1- Tapering Arm | -1.6 ± 4.92 |
| Flare Week 1- Withdrawal Arm | 3.7 ± 7.20 |
| Flare Week 2- Tapering Arm | -3.1 ± 5.41 |
| Flare Week 2- Withdrawal Arm | 0.8 ± 6.89 |
| Flare Week 3- Tapering Arm | -3.8 ± 6.78 |
| Flare Week 3- Withdrawal Arm | -0.4 ± 7.94 |
| Flare Week 5- Tapering Arm | -3.8 ± 6.61 |
| Flare Week 5- Withdrawal Arm | -0.8 ± 6.56 |
| Flare Week 6- Tapering Arm | -4.1 ± 6.81 |
| Flare Week 6- Withdrawal Arm | -0.9 ± 6.97 |
| Flare Week 7- Tapering Arm | -3.7 ± 6.86 |
| Flare Week 7- Withdrawal Arm | -0.6 ± 6.26 |
| Flare Week 8- Tapering Arm | -4.4 ± 7.17 |
| Flare Week 8- Withdrawal Arm | -0.6 ± 5.56 |
| Flare Week 9- Tapering Arm | -3.3 ± 5.81 |
| Flare Week 9- Withdrawal Arm | -1.0 ± 5.89 |
| Flare Week 11- Tapering Arm | -3.7 ± 5.69 |
| Flare Week 11- Withdrawal Arm | -1.0 ± 5.85 |
| Flare Week 12- Tapering Arm | -3.4 ± 5.84 |
| Flare Week 12- Withdrawal Arm | -2.3 ± 4.46 |
| Flare Week 13- Tapering Arm | -3.5 ± 5.72 |
| Flare Week 13- Withdrawal Arm | -2.5 ± 4.78 |
| Flare Week 14- Tapering Arm | -3.1 ± 5.54 |
| Flare Week 14- Withdrawal Arm | -2.4 ± 4.79 |
| Flare Week 15- Tapering Arm | -3.5 ± 6.69 |
| Flare Week 15- Withdrawal Arm | -2.2 ± 4.70 |
Twenty-eight joints, excluding hip joints, were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 28 (worst possible score/28 joints with swelling). Negative values indicate improvement from baseline.
| swollen joint counts | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 0.9 ± 2.09 | 0.1 ± 0.58 |
| Double Blind Week 10- Withdrawal Arm | 0.1 ± 0.33 | -0.1 ± 0.30 |
| Double Blind Week 16- Tapering Arm | 1.2 ± 2.15 | -0.0 ± 0.34 |
| Double Blind Week 16- Withdrawal Arm | 0.3 ± 0.50 | 0.0 ± 0.45 |
| Double Blind Week 22- Tapering Arm | 0.6 ± 1.64 | 0.1 ± 0.64 |
| Double Blind Week 22- Withdrawal arm | 0.5 ± 0.58 | -0.1 ± 0.30 |
| Double Blind Week 28- Tapering arm | 0.5 ± 0.89 | 0.0 ± 0.33 |
| Double Blind Week 28- Withdrawal Arm | 2.0 ± 2.45 | -0.1 ± 0.30 |
| Double Blind Week 34- Tapering Arm | 0.0 ± 0.43 | 0.0 ± 0.46 |
| Double Blind Week 34- Withdrawal Arm | 0.0 ± 0.00 | -0.1 ± 0.30 |
| Double Blind Week 40- Tapering Arm | 1.5 ± 3.01 | 0.0 ± 0.42 |
| Double Blind Week 40- Withdrawal Arm | 2.0 ± 2.83 | -0.1 ± 0.30 |
| Flare Week 0- Tapering Arm | 2.3 ± 2.60 | — |
| Flare Week 0- Withdrawal Arm | 1.9 ± 2.10 | — |
| Flare Week 4- Tapering Arm | 1.2 ± 1.98 | — |
| Flare Week 4- Withdrawal Arm | 0.6 ± 1.06 | — |
| Flare Week 10- Tapering Arm | 0.4 ± 0.89 | — |
| Flare Week 10- Withdrawal Arm | 0.1 ± 0.35 | — |
| Flare Week 16- Tapering Arm | 0.9 ± 1.81 | — |
| Flare Week 16- Withdrawal Arm | 0.3 ± 0.46 | — |
Sixty-six joints were assessed for swelling by physical examination. Swelling of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with swelling) to 66 (worst possible score/66 joints with swelling). Negative values indicate improvement from baseline.
| swollen joint counts | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 1.1 ± 2.36 | 0.1 ± 0.67 |
| Double Blind Week 10- Withdrawal Arm | 0.1 ± 0.33 | -0.2 ± 0.40 |
| Double Blind Week 16- Tapering Arm | 1.4 ± 2.56 | -0.0 ± 0.34 |
| Double Blind Week 16- Withdrawal Arm | 0.4 ± 0.53 | 0.0 ± 0.45 |
| Double Blind Week 22- Tapering Arm | 0.6 ± 1.64 | 0.1 ± 0.73 |
| Double Blind Week 22- Withdrawal arm | 1.0 ± 1.41 | -0.1 ± 0.30 |
| Double Blind Week 28- Tapering arm | 0.5 ± 0.89 | 0.1 ± 0.66 |
| Double Blind Week 28- Withdrawal Arm | 3.3 ± 4.72 | -0.2 ± 0.40 |
| Double Blind Week 34- Tapering Arm | 0.0 ± 0.43 | 0.0 ± 0.54 |
| Double Blind Week 34- Withdrawal Arm | 0.0 ± 0.00 | -0.2 ± 0.40 |
| Double Blind Week 40- Tapering Arm | 1.5 ± 3.01 | 0.0 ± 0.46 |
| Double Blind Week 40- Withdrawal Arm | 2.0 ± 2.83 | -0.2 ± 0.40 |
| Flare Week 0- Tapering Arm | 2.6 ± 2.90 | — |
| Flare Week 0- Withdrawal Arm | 2.6 ± 3.38 | — |
| Flare Week 4- Tapering Arm | 1.3 ± 1.99 | — |
| Flare Week 4- Withdrawal Arm | 0.6 ± 1.06 | — |
| Flare Week 10- Tapering Arm | 0.6 ± 1.10 | — |
| Flare Week 10- Withdrawal Arm | 0.4 ± 0.52 | — |
| Flare Week 16- Tapering Arm | 1.1 ± 2.21 | — |
| Flare Week 16- Withdrawal Arm | 0.4 ± 0.74 | — |
Twenty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 28 (worst possible score/28 joints with tenderness). Negative values indicate improvement from baseline.
| tender joint counts | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 1.3 ± 2.74 | 0.1 ± 0.54 |
| Double Blind Week 10- Withdrawal Arm | -0.1 ± 0.60 | 0.5 ± 1.21 |
| Double Blind Week 16- Tapering Arm | 2.5 ± 4.49 | 0.1 ± 0.41 |
| Double Blind Week 16- Withdrawal Arm | 1.0 ± 0.87 | 0.0 ± 0.00 |
| Double Blind Week 22- Tapering Arm | 0.9 ± 1.66 | -0.0 ± 0.42 |
| Double Blind Week 22- Withdrawal arm | 0.8 ± 1.50 | 0.1 ± 0.30 |
| Double Blind Week 28- Tapering arm | 1.6 ± 3.39 | 0.0 ± 0.51 |
| Double Blind Week 28- Withdrawal Arm | 1.8 ± 2.36 | 0.2 ± 0.40 |
| Double Blind Week 34- Tapering Arm | 1.0 ± 1.65 | -0.0 ± 0.42 |
| Double Blind Week 34- Withdrawal Arm | 0.0 ± 0.00 | 0.0 ± 0.00 |
| Double Blind Week 40- Tapering Arm | 2.0 ± 2.65 | 0.0 ± 0.51 |
| Double Blind Week 40- Withdrawal Arm | 3.5 ± 4.95 | 0.0 ± 0.00 |
| Flare Week 0- Tapering Arm | 4.4 ± 4.63 | — |
| Flare Week 0- Withdrawal Arm | 3.6 ± 3.81 | — |
| Flare Week 4- Tapering Arm | 1.5 ± 2.27 | — |
| Flare Week 4- Withdrawal Arm | 2.5 ± 5.13 | — |
| Flare Week 10- Tapering Arm | 0.9 ± 1.84 | — |
| Flare Week 10- Withdrawal Arm | 1.1 ± 1.46 | — |
| Flare Week 16- Tapering Arm | 1.8 ± 2.64 | — |
| Flare Week 16- Withdrawal Arm | 1.1 ± 1.89 | — |
Sixty-eight joints were assessed for tenderness by physical examination. Pain or tenderness of each joint was classified as present (1) or absent (0), for a total possible score of 0 (0 joints with tenderness) to 68 (worst possible score/68 joints with tenderness). Negative values indicate improvement from baseline.
| tender joint counts | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 1.9 ± 3.45 | 0.3 ± 1.47 |
| Double Blind Week 10- Withdrawal Arm | 0.1 ± 0.60 | 0.9 ± 1.64 |
| Double Blind Week 16- Tapering Arm | 3.5 ± 6.33 | 0.2 ± 1.36 |
| Double Blind Week 16- Withdrawal Arm | 1.4 ± 1.13 | 0.2 ± 0.60 |
| Double Blind Week 22- Tapering Arm | 1.2 ± 2.27 | 0.2 ± 1.35 |
| Double Blind Week 22- Withdrawal arm | 2.0 ± 2.83 | 0.4 ± 1.03 |
| Double Blind Week 28- Tapering arm | 2.5 ± 5.34 | 0.1 ± 0.96 |
| Double Blind Week 28- Withdrawal Arm | 3.8 ± 4.50 | 0.3 ± 0.47 |
| Double Blind Week 34- Tapering Arm | 1.9 ± 2.87 | 0.0 ± 0.73 |
| Double Blind Week 34- Withdrawal Arm | 0.0 ± 0.00 | 0.1 ± 0.30 |
| Double Blind Week 40- Tapering Arm | 3.0 ± 4.24 | 0.0 ± 0.68 |
| Double Blind Week 40- Withdrawal Arm | 9.0 ± 12.73 | -0.1 ± 0.30 |
| Flare Week 0- Tapering Arm | 6.2 ± 6.93 | — |
| Flare Week 0- Withdrawal Arm | 6.1 ± 6.27 | — |
| Flare Week 4- Tapering Arm | 1.9 ± 2.50 | — |
| Flare Week 4- Withdrawal Arm | 4.1 ± 8.48 | — |
| Flare Week 10- Tapering Arm | 1.5 ± 2.69 | — |
| Flare Week 10- Withdrawal Arm | 2.3 ± 2.31 | — |
| Flare Week 16- Tapering Arm | 2.1 ± 3.37 | — |
| Flare Week 16- Withdrawal Arm | 1.6 ± 1.85 | — |
Participants rated the severity of their rheumatoid arthritis symptoms and how well they were doing during the last 24 hours by placing a vertical mark on a line with a range of 0 (very well) to 100 mm (very poorly). Negative values indicate improvement from baseline.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 11.6 ± 19.00 | 2.6 ± 8.49 |
| Double Blind Week 10- Withdrawal Arm | 8.0 ± 21.66 | 9.6 ± 20.27 |
| Double Blind Week 16- Tapering Arm | 20.5 ± 26.97 | 2.4 ± 9.27 |
| Double Blind Week 16- Withdrawal Arm | 10.7 ± 19.97 | -0.3 ± 5.76 |
| Double Blind Week 22- Tapering Arm | 10.7 ± 17.74 | 1.7 ± 9.14 |
| Double Blind Week 22- Withdrawal arm | 5.8 ± 8.73 | 0.2 ± 8.87 |
| Double Blind Week 28- Tapering arm | 9.4 ± 21.03 | 2.7 ± 10.03 |
| Double Blind Week 28- Withdrawal Arm | 15.0 ± 25.76 | -1.0 ± 7.82 |
| Double Blind Week 34- Tapering Arm | 11.5 ± 13.70 | 1.2 ± 7.23 |
| Double Blind Week 34- Withdrawal Arm | -1.0 ± 1.41 | 0.7 ± 7.25 |
| Double Blind Week 40- Tapering Arm | 22.9 ± 35.32 | 0.0 ± 7.60 |
| Double Blind Week 40- Withdrawal Arm | 2.0 ± 9.90 | -1.7 ± 4.45 |
| Flare Week 0- Tapering Arm | 29.5 ± 29.43 | — |
| Flare Week 0- Withdrawal Arm | 21.6 ± 27.07 | — |
| Flare Week 4- Tapering Arm | 13.7 ± 22.93 | — |
| Flare Week 4- Withdrawal Arm | 11.7 ± 21.96 | — |
| Flare Week 10- Tapering Arm | 11.7 ± 16.89 | — |
| Flare Week 10- Withdrawal Arm | 14.1 ± 10.35 | — |
| Flare Week 16- Tapering Arm | 9.4 ± 13.47 | — |
| Flare Week 16- Withdrawal Arm | 6.9 ± 9.31 | — |
Participants rated the severity of their rheumatoid arthritis pain in the past week by placing a vertical mark on a line with a range of 0 (no pain) to 100 mm (severe pain). Negative values indicate improvement from baseline.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 8.0 ± 17.96 | 3.5 ± 14.33 |
| Double Blind Week 10- Withdrawal Arm | 6.4 ± 19.05 | 9.3 ± 21.04 |
| Double Blind Week 16- Tapering Arm | 17.8 ± 27.16 | 3.0 ± 12.48 |
| Double Blind Week 16- Withdrawal Arm | 10.7 ± 18.93 | -0.6 ± 9.65 |
| Double Blind Week 22- Tapering Arm | 10.4 ± 19.55 | 0.3 ± 7.82 |
| Double Blind Week 22- Withdrawal arm | 4.0 ± 4.90 | -1.1 ± 11.20 |
| Double Blind Week 28- Tapering arm | 8.3 ± 17.57 | 1.6 ± 9.83 |
| Double Blind Week 28- Withdrawal Arm | 14.0 ± 24.59 | -1.4 ± 10.93 |
| Double Blind Week 34- Tapering Arm | 11.6 ± 14.61 | -0.3 ± 7.61 |
| Double Blind Week 34- Withdrawal Arm | -3.5 ± 2.12 | 2.1 ± 8.40 |
| Double Blind Week 40- Tapering Arm | 24.0 ± 32.67 | -0.5 ± 10.00 |
| Double Blind Week 40- Withdrawal Arm | -0.5 ± 20.51 | -0.9 ± 5.07 |
| Flare Week 0- Tapering Arm | 24.4 ± 31.66 | — |
| Flare Week 0- Withdrawal Arm | 17.0 ± 19.38 | — |
| Flare Week 4- Tapering Arm | 9.0 ± 21.68 | — |
| Flare Week 4- Withdrawal Arm | 11.1 ± 17.46 | — |
| Flare Week 10- Tapering Arm | 7.5 ± 14.93 | — |
| Flare Week 10- Withdrawal Arm | 8.3 ± 9.60 | — |
| Flare Week 16- Tapering Arm | 8.0 ± 14.41 | — |
| Flare Week 16- Withdrawal Arm | 4.3 ± 6.32 | — |
Physicians assessed participants' current rheumatoid arthritis disease activity at the time of the visit (independent of the participant's self-assessment) by placing a vertical mark on a line with a range of 0 (very low) to 100 mm (very high). Negative values indicate improvement from baseline.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 10.2 ± 19.54 | 1.3 ± 4.27 |
| Double Blind Week 10- Withdrawal Arm | 1.6 ± 4.67 | 0.5 ± 4.74 |
| Double Blind Week 16- Tapering Arm | 13.2 ± 21.48 | 0.9 ± 5.07 |
| Double Blind Week 16- Withdrawal Arm | 5.0 ± 3.35 | -0.5 ± 2.98 |
| Double Blind Week 22- Tapering Arm | 6.9 ± 14.83 | 0.9 ± 5.05 |
| Double Blind Week 22- Withdrawal arm | 3.8 ± 2.87 | 0.4 ± 3.26 |
| Double Blind Week 28- Tapering arm | 7.3 ± 16.51 | 1.7 ± 5.51 |
| Double Blind Week 28- Withdrawal Arm | 10.0 ± 10.89 | -0.9 ± 2.74 |
| Double Blind Week 34- Tapering Arm | 5.5 ± 12.27 | 0.8 ± 3.60 |
| Double Blind Week 34- Withdrawal Arm | 0.0 ± 0.00 | 0.6 ± 4.13 |
| Double Blind Week 40- Tapering Arm | 16.2 ± 26.91 | 1.0 ± 5.32 |
| Double Blind Week 40- Withdrawal Arm | 19.5 ± 26.16 | -0.6 ± 2.42 |
| Flare Week 0- Tapering Arm | 26.5 ± 23.28 | — |
| Flare Week 0- Withdrawal Arm | 17.4 ± 15.37 | — |
| Flare Week 4- Tapering Arm | 12.2 ± 17.06 | — |
| Flare Week 4- Withdrawal Arm | 9.3 ± 20.27 | — |
| Flare Week 10- Tapering Arm | 10.2 ± 13.82 | — |
| Flare Week 10- Withdrawal Arm | 12.9 ± 11.51 | — |
| Flare Week 16- Tapering Arm | 8.6 ± 12.48 | — |
| Flare Week 16- Withdrawal Arm | 7.6 ± 20.00 | — |
The duration of morning stiffness was reported by participants as the average daily length during the past week in minutes (from time of awaking to time of maximal improvement). Negative values indicate improvement from baseline.
| minutes | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 3.5 ± 17.33 | 1.8 ± 7.19 |
| Double Blind Week 10- Withdrawal Arm | 1.1 ± 3.60 | 1.5 ± 5.97 |
| Double Blind Week 16- Tapering Arm | 6.6 ± 24.41 | 2.3 ± 12.54 |
| Double Blind Week 16- Withdrawal Arm | 9.2 ± 19.78 | -0.6 ± 5.05 |
| Double Blind Week 22- Tapering Arm | -1.6 ± 8.07 | 1.5 ± 9.67 |
| Double Blind Week 22- Withdrawal arm | 1.0 ± 2.00 | 0.5 ± 3.70 |
| Double Blind Week 28- Tapering arm | 2.6 ± 13.09 | 2.4 ± 10.53 |
| Double Blind Week 28- Withdrawal Arm | 17.3 ± 28.81 | 0.0 ± 3.71 |
| Double Blind Week 34- Tapering Arm | 0.6 ± 10.97 | 1.4 ± 8.86 |
| Double Blind Week 34- Withdrawal Arm | 0.0 ± 0.00 | -1.1 ± 6.64 |
| Double Blind Week 40- Tapering Arm | 2.0 ± 12.49 | 0.4 ± 9.33 |
| Double Blind Week 40- Withdrawal Arm | 0.0 ± 0.00 | -0.2 ± 5.78 |
| Flare Week 0- Tapering Arm | 13.5 ± 25.21 | — |
| Flare Week 0- Withdrawal Arm | 18.5 ± 26.25 | — |
| Flare Week 4- Tapering Arm | 25.0 ± 110.77 | — |
| Flare Week 4- Withdrawal Arm | 19.9 ± 26.51 | — |
| Flare Week 10- Tapering Arm | 8.1 ± 30.20 | — |
| Flare Week 10- Withdrawal Arm | 7.9 ± 9.72 | — |
| Flare Week 16- Tapering Arm | 17.3 ± 36.46 | — |
| Flare Week 16- Withdrawal Arm | 9.6 ± 20.65 | — |
Morning stiffness severity was assessed by a numeric rating-scale (NRS). Participants rated the severity of morning stiffness during the past week from 0 to 10 with 0 representing "not severe" and 10 "very severe". Negative values indicate improvement from baseline.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 0.6 ± 1.51 | 0.4 ± 1.01 |
| Double Blind Week 10- Withdrawal Arm | 0.4 ± 1.81 | 0.6 ± 1.29 |
| Double Blind Week 16- Tapering Arm | 0.8 ± 1.73 | 0.3 ± 1.11 |
| Double Blind Week 16- Withdrawal Arm | 0.7 ± 2.24 | -0.1 ± 1.04 |
| Double Blind Week 22- Tapering Arm | 0.9 ± 1.27 | 0.2 ± 0.85 |
| Double Blind Week 22- Withdrawal arm | 0.8 ± 0.96 | 0.4 ± 1.75 |
| Double Blind Week 28- Tapering arm | 0.9 ± 1.69 | 0.2 ± 1.10 |
| Double Blind Week 28- Withdrawal Arm | 1.3 ± 2.75 | -0.2 ± 0.87 |
| Double Blind Week 34- Tapering Arm | 1.3 ± 1.71 | 0.1 ± 0.85 |
| Double Blind Week 34- Withdrawal Arm | 0.0 ± 1.41 | -0.2 ± 1.08 |
| Double Blind Week 40- Tapering Arm | 1.8 ± 2.52 | 0.1 ± 0.94 |
| Double Blind Week 40- Withdrawal Arm | -1.0 ± 1.41 | -0.4 ± 1.03 |
| Flare Week 0- Tapering Arm | 1.6 ± 2.11 | — |
| Flare Week 0- Withdrawal Arm | 0.9 ± 1.96 | — |
| Flare Week 4- Tapering Arm | 0.8 ± 2.21 | — |
| Flare Week 4- Withdrawal Arm | 0.6 ± 1.72 | — |
| Flare Week 10- Tapering Arm | 0.6 ± 1.40 | — |
| Flare Week 10- Withdrawal Arm | 0.6 ± 1.27 | — |
| Flare Week 16- Tapering Arm | 0.6 ± 1.45 | — |
| Flare Week 16- Withdrawal Arm | -0.1 ± 1.13 | — |
Participants rated the severity of their sleep disturbance in the past week by placing a vertical mark on a line with a range of 0 (sleep is no problem) to 100 mm (sleep is a major problem). Negative values indicate improvement from baseline.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 2.1 ± 15.37 | 0.0 ± 8.99 |
| Double Blind Week 10- Withdrawal Arm | -3.2 ± 29.39 | 0.8 ± 1.54 |
| Double Blind Week 16- Tapering Arm | 10.2 ± 19.12 | 1.7 ± 15.96 |
| Double Blind Week 16- Withdrawal Arm | 7.1 ± 22.42 | 1.1 ± 3.02 |
| Double Blind Week 22- Tapering Arm | 8.2 ± 19.59 | -0.3 ± 10.91 |
| Double Blind Week 22- Withdrawal arm | 8.3 ± 31.35 | 3.5 ± 8.70 |
| Double Blind Week 28- Tapering arm | 1.8 ± 27.81 | 2.1 ± 12.67 |
| Double Blind Week 28- Withdrawal Arm | 4.5 ± 19.82 | -1.0 ± 7.63 |
| Double Blind Week 34- Tapering Arm | 5.6 ± 22.99 | -0.4 ± 11.48 |
| Double Blind Week 34- Withdrawal Arm | -0.5 ± 30.41 | -0.4 ± 2.77 |
| Double Blind Week 40- Tapering Arm | 17.7 ± 34.04 | -0.2 ± 12.40 |
| Double Blind Week 40- Withdrawal Arm | -8.0 ± 15.56 | -1.0 ± 4.43 |
| Flare Week 0- Tapering Arm | 18.9 ± 26.53 | — |
| Flare Week 0- Withdrawal Arm | 4.0 ± 14.61 | — |
| Flare Week 4- Tapering Arm | 4.9 ± 24.33 | — |
| Flare Week 4- Withdrawal Arm | 1.6 ± 10.05 | — |
| Flare Week 10- Tapering Arm | 0.2 ± 21.26 | — |
| Flare Week 10- Withdrawal Arm | 3.9 ± 12.98 | — |
| Flare Week 16- Tapering Arm | 2.3 ± 20.17 | — |
| Flare Week 16- Withdrawal Arm | -7.3 ± 14.14 | — |
Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 16- Tapering Arm | -8.3 ± 35.30 | 0.2 ± 23.74 |
| Double Blind Week 16- Withdrawal Arm | 2.8 ± 39.51 | -13.6 ± 43.84 |
| Double Blind Week 28- Tapering arm | -10.1 ± 24.28 | -3.8 ± 17.82 |
| Double Blind Week 28- Withdrawal Arm | -5.6 ± 45.59 | -17.2 ± 30.48 |
| Double Blind Week 40- Tapering Arm | -15.2 ± 33.53 | -4.4 ± 27.82 |
| Double Blind Week 40- Withdrawal Arm | -19.4 ± 27.50 | -16.2 ± 45.10 |
| Flare Week 0- Tapering Arm | -10.9 ± 39.82 | — |
| Flare Week 0- Withdrawal Arm | -9.5 ± 38.05 | — |
| Flare Week 4- Tapering Arm | -17.3 ± 40.07 | — |
| Flare Week 4- Withdrawal Arm | -6.5 ± 48.23 | — |
| Flare Week 10- Tapering Arm | -10.7 ± 44.07 | — |
| Flare Week 10- Withdrawal Arm | 7.9 ± 34.23 | — |
| Flare Week 16- Tapering Arm | -7.5 ± 25.49 | — |
| Flare Week 16- Withdrawal Arm | -16.7 ± 39.67 | — |
Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 16- Tapering Arm | -8.0 ± 17.25 | -0.5 ± 11.26 |
| Double Blind Week 16- Withdrawal Arm | 9.4 ± 20.04 | 2.8 ± 9.42 |
| Double Blind Week 28- Tapering arm | -2.7 ± 12.28 | 1.1 ± 7.44 |
| Double Blind Week 28- Withdrawal Arm | 14.1 ± 28.13 | 2.8 ± 9.42 |
| Double Blind Week 40- Tapering Arm | -2.3 ± 14.86 | 1.1 ± 11.61 |
| Double Blind Week 40- Withdrawal Arm | 28.1 ± 39.77 | 2.8 ± 9.42 |
| Flare Week 0- Tapering Arm | -5.1 ± 15.96 | — |
| Flare Week 0- Withdrawal Arm | 2.7 ± 7.09 | — |
| Flare Week 4- Tapering Arm | -5.0 ± 19.52 | — |
| Flare Week 4- Withdrawal Arm | 3.1 ± 7.65 | — |
| Flare Week 10- Tapering Arm | -3.7 ± 13.90 | — |
| Flare Week 10- Withdrawal Arm | 2.7 ± 7.09 | — |
| Flare Week 16- Tapering Arm | -2.0 ± 6.60 | — |
| Flare Week 16- Withdrawal Arm | 2.7 ± 7.09 | — |
Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 16- Tapering Arm | -0.2 ± 16.96 | 0.8 ± 13.45 |
| Double Blind Week 16- Withdrawal Arm | -4.9 ± 19.57 | 4.0 ± 10.86 |
| Double Blind Week 28- Tapering arm | 0.0 ± 18.70 | -1.0 ± 15.47 |
| Double Blind Week 28- Withdrawal Arm | -4.2 ± 12.32 | -3.5 ± 13.21 |
| Double Blind Week 40- Tapering Arm | -4.0 ± 9.65 | -0.1 ± 16.50 |
| Double Blind Week 40- Withdrawal Arm | -16.7 ± 23.57 | 2.5 ± 18.32 |
| Flare Week 0- Tapering Arm | 4.2 ± 12.53 | — |
| Flare Week 0- Withdrawal Arm | -7.1 ± 14.60 | — |
| Flare Week 4- Tapering Arm | 4.4 ± 19.84 | — |
| Flare Week 4- Withdrawal Arm | 5.6 ± 18.92 | — |
| Flare Week 10- Tapering Arm | 1.2 ± 10.60 | — |
| Flare Week 10- Withdrawal Arm | 0.8 ± 16.49 | — |
| Flare Week 16- Tapering Arm | 1.6 ± 19.65 | — |
| Flare Week 16- Withdrawal Arm | 0.8 ± 20.89 | — |
Participants completed the 14-item Treatment Satisfaction Questionnaire for Medication (TSQM; Version 1.4) to assess satisfaction with their current rheumatoid arthritis treatment over the previous 2-3 weeks or since the last time that they took the medication. The TSQM consists of fourteen items over four domains (effectiveness, side effects, convenience, and global satisfaction). The 14 questions are answered either with yes/no or by means of a five or seven stage scale (ranging from very unsatisfied to satisfied). TSQM Scale scores for each domain range from 0 to 100 and higher scores represent higher satisfaction. Negative values indicate worsening from baseline.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 16- Tapering Arm | -11.6 ± 24.99 | -3.4 ± 17.91 |
| Double Blind Week 16- Withdrawal Arm | -2.7 ± 15.24 | 0.6 ± 22.69 |
| Double Blind Week 28- Tapering arm | -2.2 ± 12.70 | -5.7 ± 14.97 |
| Double Blind Week 28- Withdrawal Arm | 5.4 ± 15.84 | -4.5 ± 25.81 |
| Double Blind Week 40- Tapering Arm | -3.2 ± 13.31 | -2.6 ± 15.10 |
| Double Blind Week 40- Withdrawal Arm | 0.0 ± 10.10 | -3.2 ± 21.98 |
| Flare Week 0- Tapering Arm | -11.7 ± 27.58 | — |
| Flare Week 0- Withdrawal Arm | -9.2 ± 25.66 | — |
| Flare Week 4- Tapering Arm | -3.1 ± 20.32 | — |
| Flare Week 4- Withdrawal Arm | -1.2 ± 24.08 | — |
| Flare Week 10- Tapering Arm | -0.8 ± 13.77 | — |
| Flare Week 10- Withdrawal Arm | -2.0 ± 18.77 | — |
| Flare Week 16- Tapering Arm | -6.6 ± 24.20 | — |
| Flare Week 16- Withdrawal Arm | -8.2 ± 16.72 | — |
The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in rheumatoid arthritis consisting of 6 questions, based on participant recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), overall work impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes. A negative change from baseline indicates improvement.
| percent impairment | Flared Participants | Non-Flared Participants |
|---|---|---|
| Overall Work Impairment at Week 28- Tapering Arm | 15.0 ± 21.21 | 3.5 ± 10.68 |
| Overall Work Impairment at Week 28- Withdrawal Arm | 0.0 | 0.6 ± 8.12 |
| Activity Impairment at Week 28- Tapering arm | 5.0 ± 19.51 | 2.8 ± 13.43 |
| Activity Impairment at Week 28- Withdrawal Arm | 10.0 ± 17.32 | -0.9 ± 7.01 |
| Overall Work Impairment at Week 40- Tapering Arm | — | 3.4 ± 18.78 |
| Overall Work Impairment at Week 40- Withdrawal Arm | — | 0.6 ± 8.12 |
| Activity Impairment at Week 40- Tapering arm | 15.7 ± 9.76 | 0.5 ± 13.59 |
| Activity Impairment at Week 40- Withdrawal Arm | 20.0 | 0.0 ± 6.32 |
| Overall Work Impairment Flare Wk 0- Tapering Arm | 14.0 ± 27.02 | — |
| Overall Work Impairment Flare Wk 0- Withdrawal Arm | 5.0 ± 7.07 | — |
| Activity Impairment Flare Week 0- Tapering Arm | 25.9 ± 31.57 | — |
| Activity Impairment Flare Week 0- Withdrawal Arm | 8.0 ± 25.88 | — |
| Overall Work Impairment Flare Wk 10- Tapering Arm | -0.2 ± 8.78 | — |
| Overall Work Impairment Flare W 10- Withdrawal Arm | 5.0 ± 7.07 | — |
| Activity Impairment Flare Wk 10- Tapering Arm | 6.5 ± 15.48 | — |
| Activity Impairment Flare W 10- Withdrawal Arm | 12.9 ± 13.80 | — |
| Overall Work Impairment Flare Wk 16- Tapering Arm | 10.0 ± 14.82 | — |
| Overall Work Impairment Flare W 16- Withdrawal Arm | 10.0 ± 10.00 | — |
| Activity Impairment Flare Wk 16- Tapering Arm | 11.0 ± 17.39 | — |
| Activity Impairment Flare Wk 16- Withdrawal Arm | 8.8 ± 11.26 | — |
The SF-36v2 is a non-disease specific Health Related Quality of Life (HRQoL) instrument. The SF-36v2 comprises 36 total items (questions) targeting a subject's functional health and well-being in 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health) with a recall period of four weeks. Domain scores are aggregated into a Physical Component Summary (PCS) score and a Mental Component Summary (MCS) score. SF-36v2 scores for each domain and PCS/MCS range from 0-100: higher scores indicate a better state of health and a decrease from baseline represents worsening.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 28- Tapering arm | -2.9 ± 7.53 | -1.1 ± 4.18 |
| Double Blind Week 28- Withdrawal Arm | -1.9 ± 7.39 | -2.4 ± 3.97 |
| Double Blind Week 40- Tapering Arm | -5.5 ± 6.42 | -0.4 ± 5.53 |
| Double Blind Week 40- Withdrawal Arm | -1.6 | -2.1 ± 5.22 |
| Flare Week 0- Tapering Arm | -10.8 ± 10.85 | — |
| Flare Week 0- Withdrawal Arm | -2.4 ± 10.81 | — |
| Flare Week 4- Tapering Arm | -5.2 ± 8.37 | — |
| Flare Week 4- Withdrawal Arm | -8.0 ± 7.35 | — |
| Flare Week 10- Tapering Arm | -4.0 ± 7.22 | — |
| Flare Week 10- Withdrawal Arm | -4.0 ± 4.57 | — |
| Flare Week 16- Tapering Arm | -3.8 ± 7.38 | — |
| Flare Week 16- Withdrawal Arm | -2.5 ± 2.80 | — |
The SF-36v2 is a non-disease specific Health Related Quality of Life (HRQoL) instrument. The SF-36v2 comprises 36 total items (questions) targeting a subject's functional health and well-being in 8 domains (physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health) with a recall period of four weeks. Domain scores are aggregated into a Physical Component Summary (PCS) score and a Mental Component Summary (MCS) score. SF-36v2 scores for each domain and PCS/MCS range from 0-100: higher scores indicate a better state of health and a decrease from baseline represents worsening.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 28- Tapering arm | -5.5 ± 11.31 | -0.8 ± 6.02 |
| Double Blind Week 28- Withdrawal Arm | -5.2 ± 5.90 | -0.1 ± 7.20 |
| Double Blind Week 40- Tapering Arm | -3.5 ± 11.14 | -0.8 ± 5.89 |
| Double Blind Week 40- Withdrawal Arm | -8.5 | -0.4 ± 6.71 |
| Flare Week 0- Tapering Arm | -4.1 ± 11.43 | — |
| Flare Week 0- Withdrawal Arm | 0.4 ± 4.59 | — |
| Flare Week 4- Tapering Arm | -2.0 ± 5.95 | — |
| Flare Week 4- Withdrawal Arm | -0.5 ± 2.51 | — |
| Flare Week 10- Tapering Arm | -1.1 ± 10.14 | — |
| Flare Week 10- Withdrawal Arm | -0.4 ± 3.06 | — |
| Flare Week 16- Tapering Arm | -4.0 ± 11.01 | — |
| Flare Week 16- Withdrawal Arm | 0.1 ± 2.55 | — |
The FACIT-Fatigue questionnaire is a participant questionnaire that consists of 13 questions designed to measure the degree of fatigue experienced by participants in the previous 7 days. Participants respond to the questions on a scale from 'not at all' (0) to 'very much' (4). The scale score is computed by summing the item scores, after reversing those items that are worded in the negative direction. The FACIT-Fatigue subscale score ranges from 0 to 52, where higher scores represent less fatigue. A negative change from baseline indicates worsening.
| units on a scale | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 16- Tapering Arm | -6.0 ± 9.80 | -1.5 ± 5.42 |
| Double Blind Week 16- Withdrawal Arm | -2.3 ± 3.39 | -1.9 ± 3.27 |
| Double Blind Week 28- Tapering arm | -3.5 ± 7.58 | -1.6 ± 5.60 |
| Double Blind Week 28- Withdrawal Arm | -4.3 ± 7.23 | -2.2 ± 4.67 |
| Double Blind Week 40- Tapering Arm | -6.4 ± 8.44 | -0.4 ± 4.00 |
| Double Blind Week 40- Withdrawal Arm | -2.5 ± 6.36 | -1.5 ± 4.78 |
| Flare Week 0- Tapering Arm | -7.4 ± 11.17 | — |
| Flare Week 0- Withdrawal Arm | -3.6 ± 4.75 | — |
| Flare Week 4- Tapering Arm | -3.8 ± 9.19 | — |
| Flare Week 4- Withdrawal Arm | -4.7 ± 5.43 | — |
| Flare Week 10- Tapering Arm | -3.9 ± 8.44 | — |
| Flare Week 10- Withdrawal Arm | -2.4 ± 4.47 | — |
| Flare Week 16- Tapering Arm | -4.5 ± 9.01 | — |
| Flare Week 16- Withdrawal Arm | -1.7 ± 1.89 | — |
C-Reactive Protein (CRP; mg/L) was measured from blood samples as a marker for inflammation. Higher levels are indicative of more inflammation. Negative values indicate improvement from baseline.
| mg/L | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | -7.9 ± 48.87 | 1.7 ± 12.92 |
| Double Blind Week 10- Withdrawal Arm | -0.2 ± 3.55 | -0.6 ± 2.53 |
| Double Blind Week 16- Tapering Arm | -7.4 ± 49.77 | -0.4 ± 4.26 |
| Double Blind Week 16- Withdrawal Arm | 6.6 ± 12.26 | -0.1 ± 3.67 |
| Double Blind Week 22- Tapering Arm | 3.6 ± 9.69 | -0.0 ± 5.43 |
| Double Blind Week 22- Withdrawal arm | 0.6 ± 0.37 | -0.9 ± 3.38 |
| Double Blind Week 28- Tapering arm | 0.5 ± 3.85 | -0.4 ± 4.65 |
| Double Blind Week 28- Withdrawal Arm | 1.1 ± 1.34 | 2.5 ± 11.60 |
| Double Blind Week 34- Tapering Arm | 3.2 ± 10.13 | -0.4 ± 4.41 |
| Double Blind Week 34- Withdrawal Arm | 1.8 ± 1.89 | 0.3 ± 5.98 |
| Double Blind Week 40- Tapering Arm | 1.0 ± 5.69 | -0.3 ± 4.18 |
| Double Blind Week 40- Withdrawal Arm | 8.3 ± 11.60 | -0.1 ± 3.43 |
| Flare Week 0- Tapering Arm | -7.4 ± 54.12 | — |
| Flare Week 0- Withdrawal Arm | 5.4 ± 12.67 | — |
| Flare Week 4- Tapering Arm | -8.5 ± 55.47 | — |
| Flare Week 4- Withdrawal Arm | -1.3 ± 4.01 | — |
| Flare Week 10- Tapering Arm | -9.5 ± 55.61 | — |
| Flare Week 10- Withdrawal Arm | -0.6 ± 0.97 | — |
| Flare Week 16- Tapering Arm | -9.1 ± 53.70 | — |
| Flare Week 16- Withdrawal Arm | -0.8 ± 2.74 | — |
Erythrocyte sedimentation rate (ESR; mm/hour) indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. Negative values indicate improvement from baseline.
| mm/hour | Flared Participants | Non-Flared Participants |
|---|---|---|
| Double Blind Week 10- Tapering Arm | 4.1 ± 11.25 | 0.7 ± 5.22 |
| Double Blind Week 10- Withdrawal Arm | 0.9 ± 9.24 | -1.5 ± 5.43 |
| Double Blind Week 16- Tapering Arm | 4.6 ± 10.73 | 0.5 ± 5.82 |
| Double Blind Week 16- Withdrawal Arm | 5.2 ± 15.23 | -0.3 ± 5.31 |
| Double Blind Week 22- Tapering Arm | 3.5 ± 10.73 | -0.5 ± 7.38 |
| Double Blind Week 22- Withdrawal arm | 2.8 ± 9.22 | -0.3 ± 4.22 |
| Double Blind Week 28- Tapering arm | 3.4 ± 8.18 | 0.4 ± 6.93 |
| Double Blind Week 28- Withdrawal Arm | 6.0 ± 10.10 | 1.0 ± 5.04 |
| Double Blind Week 34- Tapering Arm | 4.8 ± 7.28 | 0.3 ± 7.57 |
| Double Blind Week 34- Withdrawal Arm | -5.0 ± 1.41 | -0.5 ± 5.94 |
| Double Blind Week 40- Tapering Arm | 10.2 ± 13.22 | 1.4 ± 7.19 |
| Double Blind Week 40- Withdrawal Arm | -2.0 ± 5.66 | 4.7 ± 8.89 |
| Flare Week 0- Tapering Arm | 10.4 ± 12.50 | — |
| Flare Week 0- Withdrawal Arm | 13.0 ± 11.90 | — |
| Flare Week 4- Tapering Arm | 7.2 ± 9.82 | — |
| Flare Week 4- Withdrawal Arm | 8.5 ± 9.52 | — |
| Flare Week 10- Tapering Arm | 5.8 ± 10.16 | — |
| Flare Week 10- Withdrawal Arm | 4.4 ± 6.91 | — |
| Flare Week 16- Tapering Arm | 8.0 ± 10.95 | — |
| Flare Week 16- Withdrawal Arm | 7.0 ± 14.40 | — |
Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 70 days after the last dose of study drug in the Double-blind Period (up to 50 weeks); for participants who experienced flare during the double-blind period, AEs were collected until 70 days after the last dose of study drug in the 16-week Open-label Rescue Period (up to 66 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab 40 mg Eow | 0/146 (0%) | 4/146 (2.7%) | 11/146 (7.5%) |
| Adalimumab Tapering | 0/102 (0%) | 1/102 (1%) | 33/102 (32.4%) |
| Adalimumab Withdrawal Arm | 0/20 (0%) | 0/20 (0%) | 12/20 (60%) |
| Adalimumab 40 mg Eow Rescue Arm | 0/39 (0%) | 3/39 (7.7%) | 13/39 (33.3%) |
| Event | Adalimumab 40 mg Eow | Adalimumab Tapering | Adalimumab Withdrawal Arm | Adalimumab 40 mg Eow Rescue Arm |
|---|---|---|---|---|
| RETINAL VEIN OCCLUSIONEye disorders | 0/146 | 0/102 | 0/20 | 1/39 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 0/146 | 0/102 | 0/20 | 1/39 |
| PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders | 0/146 | 0/102 | 0/20 | 1/39 |
| BREAST CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/146 | 1/102 | 0/20 | 0/39 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/146 | 0/102 | 0/20 | 0/39 |
| PNEUMONIAInfections and infestations | 1/146 | 0/102 | 0/20 | 0/39 |
| COMMINUTED FRACTUREInjury, poisoning and procedural complications | 1/146 | 0/102 | 0/20 | 0/39 |
| TRANSIENT ISCHAEMIC ATTACKNervous system disorders | 1/146 | 0/102 | 0/20 | 0/39 |
| Event | Adalimumab 40 mg Eow | Adalimumab Tapering | Adalimumab Withdrawal Arm | Adalimumab 40 mg Eow Rescue Arm |
|---|---|---|---|---|
| NASOPHARYNGITISInfections and infestations | 4/146 | 16/102 | 4/20 | 4/39 |
| INFLUENZAInfections and infestations | 0/146 | 5/102 | 2/20 | 0/39 |
| LIMB INJURYInjury, poisoning and procedural complications | 0/146 | 0/102 | 2/20 | 1/39 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 0/146 | 1/102 | 0/20 | 3/39 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 0/146 | 6/102 | 0/20 | 1/39 |
| URINARY TRACT INFECTIONInfections and infestations | 2/146 | 0/102 | 0/20 | 2/39 |
| HEPATIC ENZYME INCREASEDInvestigations | 0/146 | 0/102 | 0/20 | 2/39 |
| OEDEMA PERIPHERALGeneral disorders | 0/146 | 0/102 | 1/20 | 1/39 |
| LOWER RESPIRATORY TRACT INFECTIONInfections and infestations | 1/146 | 3/102 | 1/20 | 1/39 |
| PHARYNGOTONSILLITISInfections and infestations | 0/146 | 0/102 | 1/20 | 0/39 |
All Lead-in-Treated Subject population: participants who were enrolled in the study and received at least 1 dose of study drug during the Lead-in period
| Age, Continuous(years) | Adalimumab 40 mg Eow |
|---|---|
| Mean | 59.6 ± 10.30 |
| Sex: Female, Male(Participants) | Adalimumab 40 mg Eow |
|---|---|
| Female | 109 |
| Male | 37 |
| Race (NIH/OMB)(Participants) | Adalimumab 40 mg Eow |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 139 |
| More than one race | 0 |
| Unknown or Not Reported | 3 |
| Tobacco Use(Participants) | Adalimumab 40 mg Eow |
|---|---|
| Current | 22 |
| Former | 46 |
| Never | 76 |
| Unknown | 2 |
| Disease duration(years) | Adalimumab 40 mg Eow |
|---|---|
| Mean | 12.9 ± 9.99 |
| Duration of adalimumab therapy(years) | Adalimumab 40 mg Eow |
|---|---|
| Mean | 5.4 ± 3.27 |
| Duration of remission(years) | Adalimumab 40 mg Eow |
|---|---|
| Mean | 2.2 ± 1.99 |
| Previous treatment with conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs)(Participants) | Adalimumab 40 mg Eow |
|---|---|
| Yes | 145 |
| No | 1 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Data sharing details ↗ · www.abbvie.com
Ran from Jan 2015 to primary completion in May 2018, 39 months.
Results were first posted in Jun 2019, 1 year 1 month after primary completion.
Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 39 months is above that.
Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab